Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators

There is an increasing amount of evidence to support that activation of the metabotropic glutamate receptor 4 (mGlu4 receptor), either with an orthosteric agonist or a positive allosteric modulator (PAM), provides impactful interventions in diseases such as Parkinson's disease, anxiety, and pain. mGlu4 PAMs may have several advantages over mGlu4 agonists for a number of reasons. As part of our efforts in identifying therapeutics for central nervous system (CNS) diseases such as Parkinson's disease, we have been focusing on Metabotropic Glutamate Receptors. Herein we report our studies with a series of tricyclic thiazolopyrazoles as mGlu4 PAMs.